US Patent 11,707,451: Mirabegron Sustained-Release Patent Scope, Validity Risks, and Generic Entry Analysis

US Patent 11,707,451 covers oral treatment of overactive bladder with sustained-release mirabegron designed to reduce the food effect associated with immediate-release mirabegron. The independent claim is a method-of-treatment claim with a broad formulation Markush, but its enforceability depends on proving four linked limitations: the mirabegron identity and dose, sustained release for at least four hours, administration in tablet form, and reduced food effect relative to an immediate-release formulation.

The strongest commercial risk is directed to sustained-release mirabegron products using hydrogel, matrix, osmotic, multilayer, coated, or swelling-polymer technologies. Conventional immediate-release mirabegron products do not necessarily infringe because the claims require sustained release and a reduced food effect.

What drug does US Patent 11,707,451 protect?

The claimed active ingredient is mirabegron, identified by its chemical name:

(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide

Mirabegron is the active ingredient in Myrbetriq and Myrbetriq Granules, marketed for overactive bladder and neurogenic detrusor overactivity. It is a beta-3 adrenergic receptor agonist.

Item	Claim scope
Active ingredient	The specified R-enantiomer of mirabegron
Therapeutic indication	Overactive bladder
Route	Oral
Dosage form	Tablet
Dose range	10 mg to 200 mg
Preferred claimed doses	25 mg and 50 mg
Release profile	Continuous drug release for at least four hours
Food-effect objective	Reduced food effect versus immediate-release mirabegron
Formulation types	Hydrogel, multilayer, gum-based gel, osmotic pump, swelling-polymer, soluble-polymer matrix, coated modified-release, and insoluble-polymer matrix

The claims do not cover every mirabegron product. They require a sustained-release formulation and a comparative food-effect limitation.

What does claim 1 of US 11,707,451 require?

Claim 1 contains several cumulative limitations. A potentially infringing product must satisfy each limitation or its legal equivalent.

1. Treatment of overactive bladder

The claim is limited to treating overactive bladder. Use for hypertension, heart failure, or another beta-3 agonist indication would not satisfy this limitation unless the product is also used for overactive bladder.

2. Oral administration to a patient

The method requires oral administration to a subject in need of treatment. The claim therefore focuses on administration, not merely the manufacture or sale of a formulation.

A formulation manufacturer may face indirect infringement exposure if it supplies a product with instructions encouraging the claimed use. Direct method infringement generally requires performance of the claimed administration step.

3. Tablet dosage form

The claimed product must be a tablet. Capsules, liquids, injectables, transdermal systems, and other dosage forms fall outside the literal scope unless a court applies an equivalent theory.

The tablet limitation narrows the claim materially. A sustained-release capsule containing an otherwise identical formulation would present a noninfringement position based on dosage form, although the outcome would depend on claim construction and the actual product structure.

4. Mirabegron dose of 10 mg to 200 mg

The broad dose range covers 10 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, among other doses within the range.

Claims 2 and 3 narrow the dose to 25 mg and 50 mg. These dependent claims are commercially important because 25 mg and 50 mg correspond to the principal dose strengths associated with marketed mirabegron therapy.

5. Sustained-release formulation

The formulation must provide continuous drug release for at least four hours after oral administration. The claim does not specify a single dissolution method, release percentage, or pharmacokinetic threshold in the text supplied.

That creates an evidence issue. In litigation, the patent holder would likely need dissolution data, in vivo release data, or other analytical evidence showing that the accused product provides continuous release for the required period.

6. Reduced food effect

The claim requires reduced food effect compared with an immediate-release formulation containing the same mirabegron active ingredient.

This is a functional and comparative limitation. The relevant comparison is not necessarily the marketed Myrbetriq product. The claim language identifies an immediate-release mirabegron formulation as the comparator.

A generic developer could challenge infringement by arguing that:

the accused product does not have a reduced food effect;
the claimed comparator is not properly defined;
the product’s food effect is not statistically or clinically reduced;
the product does not meet the patent’s construction of “continuous drug release”; or
the product is not a tablet or does not use a listed formulation type.

What formulations are protected by US Patent 11,707,451?

Claim 1 uses a broad list of formulation architectures. The listed alternatives are not limited to one specific polymer, excipient, coating thickness, geometry, or manufacturing process.

Formulation category	Likely technical concept	Primary design-around issue
Hydrogel-forming formulation	Polymer hydrates and forms a diffusion or erosion barrier	Select a non-hydrogel release system
Multilayer formulation	Drug core and release-controlling layer arranged geometrically	Use a homogeneous matrix or capsule
Gum-based gel	Multiple gums control hydration and drug diffusion	Use a non-gum polymer system
Osmotic pump	Osmotic pressure drives controlled release	Use non-osmotic diffusion or erosion
Swelling-polymer formulation	Polymer expands after hydration	Use a non-swelling matrix
Water-soluble polymer matrix	Soluble polymer controls release through hydration and erosion	Use insoluble or lipid-based technology
Coated modified-release formulation	Membrane coating controls release	Use uncoated matrix or alternate dosage form
Insoluble-polymer matrix	Drug diffuses from a non-soluble polymeric network	Use a soluble, lipid, or nonpolymeric system

The formulation list is drafted as a Markush group. A product using any one of the listed categories may fall within claim 1 if the remaining limitations are met. The claim does not appear limited to a particular hydrogel polymer such as hypromellose, polyethylene oxide, carbomer, or a specific combination of excipients.

How strong are claims 2 through 6?

Claims 2 through 6 provide narrower positions that may be more practical in enforcement.

Claim	Added limitation	Commercial relevance
1	10-200 mg tablet with specified sustained-release and food-effect features	Broadest claim
2	25 mg tablet	Covers a principal low-dose strength
3	50 mg tablet	Covers a principal higher-dose strength
4	Hydrogel-forming formulation	Narrows claim 1 to hydrogel systems
5	25 mg hydrogel tablet	Combined dose and formulation protection
6	50 mg hydrogel tablet	Combined dose and formulation protection

The narrowest claims, claims 5 and 6, may be easier to prove against a product that uses a hydrogel tablet at a 25 mg or 50 mg dose. They are also more vulnerable to invalidity arguments based on prior art directed to conventional hydrogel sustained-release tablets.

Claim 1 has wider coverage but greater proof complexity because it combines the formulation category with the reduced-food-effect result.

Is US Patent 11,707,451 a composition patent or a method patent?

US 11,707,451 is directed to method claims, not a conventional composition claim.

The claims require administering the tablet to treat overactive bladder. They do not expressly claim:

the tablet as a standalone article;
a specific polymer composition;
a manufacturing process;
a dissolution profile with numerical specifications;
a pharmacokinetic AUC or Cmax ratio; or
a particular excipient concentration.

This distinction affects both enforcement and Orange Book analysis. A method claim may be eligible for listing if it is sufficiently tied to an approved drug product and approved use, but listing depends on FDA Orange Book standards and the patent information submitted by the NDA holder. The patent number alone does not establish that FDA lists it for Myrbetriq.

What is the Orange Book status of US Patent 11,707,451?

The patent should be evaluated against the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, for the applicable mirabegron NDA.

The relevant questions are:

Whether US 11,707,451 is listed against the mirabegron NDA.
Whether the listing covers Myrbetriq tablets, Myrbetriq Granules, or another approved dosage form.
Whether FDA identifies the patent as a drug-substance, drug-product, formulation, or method-of-use patent.
Whether the patent has an expiration date, pediatric extension, or delisting event recorded in the Orange Book.
Whether an applicant must certify under Paragraph IV for a generic product that references the relevant NDA.

A method-of-use patent may create a Paragraph IV issue if the proposed generic labeling includes the patented overactive-bladder use. A section viii “carve-out” may be possible only if the patented use can be omitted without rendering the proposed label inconsistent with the approved product’s nonpatented uses.

The patent claim supplied is specifically directed to treating overactive bladder. That makes label strategy central to any abbreviated new drug application.

When does US Patent 11,707,451 lose exclusivity?

The statutory expiration date cannot be reliably calculated from the patent number and claims alone. The controlling date appears on the patent’s front page and in USPTO Patent Center, subject to patent-term adjustment, terminal disclaimers, patent-term extension, and any applicable pediatric exclusivity.

For commercial analysis, the relevant date is the earliest enforceable loss-of-exclusivity date among:

Exclusivity component	Relevance
Patent expiration	Ends ordinary patent enforceability
Patent-term adjustment	May extend the 20-year term for USPTO delay
Patent-term extension	May extend certain regulatory-delay periods
Pediatric exclusivity	Adds six months to eligible listed exclusivities
Terminal disclaimer	Can limit the term to another patent
Settlement restrictions	May establish an earlier or later agreed launch date
Regulatory exclusivity	May block approval independently of patent rights

A reliable launch model must use the current Orange Book and USPTO records rather than an expiration estimate derived solely from the issue date.

What Paragraph IV challenges could target this patent?

A generic applicant could challenge US 11,707,451 under Paragraph IV on several grounds.

Lack of written description or enablement

The claim covers several unrelated sustained-release architectures, including osmotic, multilayer, gum-based, soluble-polymer, and insoluble-polymer systems. A challenger could argue that the specification does not enable the full breadth of the Markush group or does not provide adequate support for reduced food effect across the entire claimed dose and formulation range.

Obviousness

The principal obviousness theory would combine:

known mirabegron treatment for overactive bladder;
known sustained-release tablet technologies;
known methods for reducing food effects;
routine dose strengths such as 25 mg and 50 mg; and
standard hydrogel or matrix excipients.

The patent holder would likely rely on unexpected pharmacokinetic results, reduced fed/fasted variability, improved tolerability, or a specific relationship between release duration and food-effect reduction.

Indefiniteness

“Reduced food effect” may be challenged if the patent does not define the measurement, comparator, statistical test, or magnitude of reduction with sufficient precision.

“Continuous drug release for at least 4 hours” may also face an indefiniteness or claim-construction dispute if the specification does not identify a reproducible test method.

Anticipation

A single prior-art reference would need to disclose the complete combination, including the specific R-mirabegron active ingredient, tablet, dose, sustained release for at least four hours, reduced food effect relative to immediate release, and one of the listed formulation categories.

A conventional sustained-release mirabegron reference that lacks the food-effect comparison may not anticipate the claim, although it could remain relevant to obviousness.

What patent litigation affects mirabegron generic entry?

The principal litigation risk is a Paragraph IV action brought by the NDA holder or patent owner after receiving a generic certification notice.

Under the Hatch-Waxman framework:

A generic applicant submits an ANDA referencing the approved mirabegron product.
The applicant certifies that listed patents are invalid, unenforceable, or not infringed, or seeks a label carve-out.
The patent owner may sue within 45 days.
A timely suit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court developments.
The parties may settle with an agreed launch date, license, or other market-access arrangement.

The supplied claim is particularly relevant to a generic seeking approval for a sustained-release mirabegron tablet. It is less directly relevant to a generic that uses the same active ingredient in an immediate-release product or a non-tablet dosage form.

No settlement date, court docket, Paragraph IV notice, or final judgment can be attributed to US 11,707,451 from the claim text alone. Such events must be confirmed through PACER, FDA Orange Book updates, SEC filings, and the patent owner’s public disclosures.

Are biosimilar risks relevant to US 11,707,451?

No. Mirabegron is a small-molecule drug, not a biologic. Biosimilar pathways under the Public Health Service Act and Purple Book do not apply.

The relevant competitive pathways are:

ANDA approval under section 505(j);
505(b)(2) applications for modified-release or different dosage forms;
branded reformulation strategies; and
authorized generic commercialization.

A sustained-release mirabegron product that differs materially from the reference product may require a 505(b)(2) application rather than an ANDA, depending on the formulation, clinical evidence, and reference-product relationship.

How does this patent compare with the broader mirabegron patent estate?

US 11,707,451 appears to occupy the formulation and pharmacokinetic portion of the estate rather than the foundational chemical-compound portion.

Estate segment	Typical protection	Relevance to US 11,707,451
Compound patents	Mirabegron molecule and salts	Separate foundational protection
Therapeutic-use patents	OAB, urinary urgency, bladder dysfunction	Claim 1 overlaps through OAB treatment
Formulation patents	Sustained release, matrices, coatings, osmotic systems	Core subject of US 11,707,451
Dose patents	25 mg, 50 mg, titration, dosing regimens	Claims 2 and 3 provide dose-specific coverage
Manufacturing patents	Synthesis, intermediates, crystallization	Not claimed in the supplied claims
Combination patents	Mirabegron with another active agent	Not claimed
Pediatric formulations	Granules, suspensions, sprinkle dosage forms	Not covered by the tablet limitation

Patent-estate analysis should distinguish patent expiration from commercial exclusivity. A foundational compound patent may expire before a formulation patent, leaving a generic exposed to later-entry risk if it uses the patented sustained-release configuration.

What generic launch scenarios exist?

Immediate-release generic

An immediate-release generic may avoid literal infringement because claim 1 requires a sustained-release tablet and at least four hours of continuous release. Regulatory feasibility would depend on whether an immediate-release mirabegron product is an approved reference or otherwise supportable under the applicable FDA pathway.

Conventional extended-release generic

A conventional extended-release tablet may face substantial risk if it uses a listed polymer system and demonstrates reduced food effect relative to immediate release.

Hydrogel-based generic

A hydrogel product at 25 mg or 50 mg presents the highest direct exposure to claims 4 through 6. A design-around would need to address both the hydrogel limitation and the comparative food-effect limitation.

Non-tablet product

A capsule, suspension, or other dosage form may avoid the tablet limitation but could face separate patents, regulatory requirements, or infringement theories under other patent families.

505(b)(2) reformulation

A modified-release product with a different release mechanism could require new clinical or pharmacokinetic evidence. It may avoid this patent if it does not satisfy the claim limitations, but it could encounter other formulation patents.

How strong is the patent estate represented by US 11,707,451?

The patent has meaningful commercial value if three conditions are met:

It remains enforceable through the relevant generic-launch period.
It is listed or otherwise usable in Hatch-Waxman litigation.
The claimed reduced food-effect limitation can be proven with reproducible comparative data.

Its main strengths are the broad formulation Markush and explicit coverage of 25 mg and 50 mg tablets. Its main vulnerabilities are the functional food-effect limitation, the breadth of the formulation alternatives, and the method-of-treatment format.

The most defensible enforcement position is likely against a 25 mg or 50 mg hydrogel sustained-release tablet that is labeled for overactive bladder and has clinical data showing reduced fed/fasted variability compared with immediate-release mirabegron.

Key Takeaways

US 11,707,451 covers treatment of overactive bladder with sustained-release oral mirabegron tablets.
Claim 1 requires 10-200 mg of mirabegron, at least four hours of continuous release, and reduced food effect versus immediate-release mirabegron.
Claims 2 and 3 specifically cover 25 mg and 50 mg tablets.
Claims 4 through 6 focus on hydrogel-forming systems, including 25 mg and 50 mg hydrogel tablets.
Immediate-release products and non-tablet products have stronger noninfringement positions under the supplied claims.
Generic exposure is highest for hydrogel, matrix, coated, multilayer, osmotic, and swelling-polymer sustained-release tablets.
The patent is a method patent, not a standalone composition or manufacturing patent.
Orange Book listing and the operative expiration date must be confirmed from current FDA and USPTO records.
Biosimilar analysis is not applicable because mirabegron is a small molecule.
The principal legal risks are obviousness, enablement, written description, indefiniteness, and proof of reduced food effect.

FAQs

Can a generic mirabegron tablet avoid US 11,707,451 by using a different polymer?

Potentially. A different polymer may avoid a specific formulation limitation, but claim 1 lists broad formulation categories rather than particular polymers. The product would still need to avoid the tablet, sustained-release, dose, OAB-use, and reduced-food-effect limitations.

Does a 25 mg mirabegron product automatically infringe claim 2?

No. The product must also be a tablet, treat overactive bladder, use sustained release for at least four hours, and provide reduced food effect relative to immediate-release mirabegron.

Can a generic carve out the overactive-bladder indication?

A carve-out is legally possible only if the patented use can be omitted while preserving an approvable and commercially viable label. Because the supplied claims are directed specifically to overactive bladder, the feasibility of a section viii statement would require close comparison of the reference label and all other listed patents.

Does US 11,707,451 cover Myrbetriq Granules?

The supplied claims require a tablet. Myrbetriq Granules would not literally satisfy the tablet limitation, although the granule product may be subject to separate patents or regulatory protections.

What evidence would be most important in a Paragraph IV case?

The central evidence would include the accused product’s dissolution profile, fed and fasted pharmacokinetic data, formulation composition, dosage form, labeling, and the patent specification’s definitions of reduced food effect and continuous release.

References

Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (n.d.). Myrbetriq prescribing information. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.
United States Patent No. 11,707,451. (2023). Sustained-release mirabegron treatment for overactive bladder with reduced food effect. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Guidance for industry. U.S. Department of Health and Human Services.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2554168	⤷ Start Trial
Spain	2665467	⤷ Start Trial
Japan	5849947	⤷ Start Trial
Japan	WO2011122524	⤷ Start Trial
Poland	2554168	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 11,707,451